BMS rises on growth potential despite revenue declines from patent losses
This article was originally published in Scrip
Bristol-Myers Squibb reported on 24 January that 2012 sales ended up significantly lower than in the previous year and 2013 revenue will be lower still, but investors seemed happy with the company's guidance for this year and plans to make up for the earnings slide caused by blockbuster drug patent expirations.
You may also be interested in...
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
The $80m financing will support a Phase III myelofibrosis study for the LSD1 inhibitor and earlier-stage programs, but additional late-stage studies will require an initial public offering, likely next year.